A genetic locus in 7p12.2 associated with treatment resistant schizophrenia

Schizophrenia Research

Volumn 159, Issue 2-3, 2014, Pages 333-339

  Li, Jiang ^a   Meltzer, Herbert Y ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Clozapine; Dopa decarboxylase; Genetic; Genome wide association study; Schizophrenia; Treatment resistant

Indexed keywords

AMINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BIOLOGICAL MARKER; DNA; NEUROTRANSMITTER;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CHROMOSOME 7P; CHROMOSOME 7P12.2; CONTROLLED STUDY; DNA FLANKING REGION; ENZYME SYNTHESIS; FEMALE; GENE LOCATION; GENE LOCUS; GENE REPLICATION; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PREFRONTAL CORTEX; QUANTITATIVE TRAIT LOCUS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESISTANT SCHIZOPHRENIA;

EID: 84922475323     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.08.018     Document Type: Article

References (40)

1. Arnaud P., Monk D., Hitchins M., Gordon E., Dean W., Beechey C.V., Peters J., Craigen W., Preece M., Stanier P., Moore G.E., Kelsey G. Conserved methylation imprints in the human and mouse GRB10 genes with divergent allelic expression suggests differential reading of the same mark. Hum. Mol. Genet. 2003, 12(9):1005-1019.
2. Berry M.D. The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Rev. Recent Clin. Trials 2007, 2(1):3-19.
3. Blagitko N., Mergenthaler S., Schulz U., Wollmann H.A., Craigen W., Eggermann T., Ropers H.H., Kalscheuer V.M. Human GRB10 is imprinted and expressed from the paternal and maternal allele in a highly tissue- and isoform-specific fashion. Hum. Mol. Genet. 2000, 9(11):1587-1595.
4. Borglum A.D., Hampson M., Kjeldsen T.E., Muir W., Murray V., Ewald H., Mors O., Blackwood D., Kruse T.A. Dopa decarboxylase genotypes may influence age at onset of schizophrenia. Mol. Psychiatry 2001, 6(6):712-717.
5. Colantuoni C., Lipska B.K., Ye T., Hyde T.M., Tao R., Leek J.T., Colantuoni E.A., Elkahloun A.G., Herman M.M., Weinberger D.R., Kleinman J.E. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature 2011, 478(7370):519-523.
6. Conley R.R., Kelly D.L. Management of treatment resistance in schizophrenia. Biol. Psychiatry 2001, 50(11):898-911.
7. Davis B.A., Shrikhande S., Paralikar V.P., Hirsch S.R., Durden D.A., Boulton A.A. Phenylacetic acid in CSF and serum in Indian schizophrenic patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1991, 15(1):41-47.
8. Fox C.S., Heard-Costa N., Cupples L.A., Dupuis J., Vasan R.S., Atwood L.D. Genome-wide association to body mass index and waist circumference: the Framingham Heart Study 100K project. BMC Med. Genet. 2007, 8(Suppl. 1):S18.
9. Garfield A.S., Cowley M., Smith F.M., Moorwood K., Stewart-Cox J.E., Gilroy K., Baker S., Xia J., Dalley J.W., Hurst L.D., Wilkinson L.S., Isles A.R., Ward A. Distinct physiological and behavioural functions for parental alleles of imprinted Grb10. Nature 2011, 469(7331):534-538.
10. Grunder G., Vernaleken I., Muller M.J., Davids E., Heydari N., Buchholz H.G., Bartenstein P., Munk O.L., Stoeter P., Wong D.F., Gjedde A., Cumming P. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 2003, 28(4):787-794.
11. Hietala J., Syvalahti E., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Kirvela O., Ruotsalainen U., et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995, 346(8983):1130-1131.
12. Hietala J., Syvalahti E., Vilkman H., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Eronen E., Ruotsalainen U., Salokangas R.K. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr. Res. 1999, 35(1):41-50.
13. Hitzemann R., Dains K., Bier-Langing C.M., Zahniser N.R. On the selection of mice for haloperidol response and non-response. Psychopharmacology 1991, 103(2):244-250.
14. Ikemoto K., Nishimura A., Oda T., Nagatsu I., Nishi K. Number of striatal D-neurons is reduced in autopsy brains of schizophrenics. Leg. Med. (Tokyo) 2003, 5(Suppl. 1):S221-S224.
15. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45(9):789-796.
16. Kane J.M., Honigfeld G., Singer J., Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol. Bull. 1988, 24(1):62-67.
17. Kolakowska T., Williams A.O., Ardern M., Reveley M.A., Jambor K., Gelder M.G., Mandelbrote B.M. Schizophrenia with good and poor outcome. I: early clinical features, response to neuroleptics and signs of organic dysfunction. Br. J. Psychiatry J. Ment. Sci. 1985, 146:229-239.
18. Lindstrom L.H., Gefvert O., Hagberg G., Lundberg T., Bergstrom M., Hartvig P., Langstrom B. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by l-(beta-11C) DOPA and PET. Biol. Psychiatry 1999, 46(5):681-688.
19. Maunakea A.K., Nagarajan R.P., Bilenky M., Ballinger T.J., D'Souza C., Fouse S.D., Johnson B.E., Hong C., Nielsen C., Zhao Y., Turecki G., Delaney A., Varhol R., Thiessen N., Shchors K., Heine V.M., Rowitch D.H., Xing X., Fiore C., Schillebeeckx M., Jones S.J., Haussler D., Marra M.A., Hirst M., Wang T., Costello J.F. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010, 466(7303):253-257.
20. McGowan S., Lawrence A.D., Sales T., Quested D., Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch. Gen. Psychiatry 2004, 61(2):134-142.
21. Meltzer H.Y. Treatment-resistant schizophrenia-the role of clozapine. Curr. Med. Res. Opin. 1997, 14(1):1-20.
22. Meltzer H.Y. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 2013, 64:393-406.
23. Meltzer H.Y., Rabinowitz J., Lee M.A., Cola P.A., Ranjan R., Findling R.L., Thompson P.A. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am. J. Psychiatry 1997, 154(4):475-482.
24. Meltzer H.Y., Lee M., Cola P. The evolution of treatment resistance: biologic implications. J. Clin. Psychopharmacol. 1998, 18(2 Suppl 1):5S-11S.
25. Menheniott T.R., Woodfine K., Schulz R., Wood A.J., Monk D., Giraud A.S., Baldwin H.S., Moore G.E., Oakey R.J. Genomic imprinting of Dopa decarboxylase in heart and reciprocal allelic expression with neighboring Grb10. Mol. Cell. Biol. 2008, 28(1):386-396.
26. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 2002, 5(3):267-271.
27. Miller G.M. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J. Neurochem. 2011, 116(2):164-176.
28. Neff N.H., Wemlinger T.A., Hadjiconstantinou M. SCH 23390 enhances exogenous l-DOPA decarboxylation in nigrostriatal neurons. J. Neural Transm. 2000, 107(4):429-443.
29. Neff N.H., Wemlinger T.A., Duchemin A.M., Hadjiconstantinou M. Clozapine modulates aromatic l-amino acid decarboxylase activity in mouse striatum. J. Pharmacol. Exp. Ther. 2006, 317(2):480-487.
30. Northup A., Nimgaonkar V.L. Genetics of schizophrenia: implications for treatment. Expert. Rev. Neurother. 2004, 4(4):725-731.
31. O'Reilly R., Davis B.A., Durden D.A., Thorpe L., Machnee H., Boulton A.A. Plasma phenylethylamine in schizophrenic patients. Biol. Psychiatry 1991, 30(2):145-150.
32. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460(7256):748-752.
33. Rampersaud E., Damcott C.M., Fu M., Shen H., McArdle P., Shi X., Shelton J., Yin J., Chang Y.P., Ott S.H., Zhang L., Zhao Y., Mitchell B.D., O'Connell J., Shuldiner A.R. Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes 2007, 56(12):3053-3062.
34. Reith J., Benkelfat C., Sherwin A., Yasuhara Y., Kuwabara H., Andermann F., Bachneff S., Cumming P., Diksic M., Dyve S.E., Etienne P., Evans A.C., Lal S., Shevell M., Savard G., Wong D.F., Chouinard G., Gjedde A. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(24):11651-11654.
35. Revel F.G., Moreau J.L., Gainetdinov R.R., Bradaia A., Sotnikova T.D., Mory R., Durkin S., Zbinden K.G., Norcross R., Meyer C.A., Metzler V., Chaboz S., Ozmen L., Trube G., Pouzet B., Bettler B., Caron M.G., Wettstein J.G., Hoener M.C. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(20):8485-8490.
36. Revel F.G., Moreau J.L., Pouzet B., Mory R., Bradaia A., Buchy D., Metzler V., Chaboz S., Groebke Zbinden K., Galley G., Norcross R.D., Tuerck D., Bruns A., Morairty S.R., Kilduff T.S., Wallace T.L., Risterucci C., Wettstein J.G., Hoener M.C. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol. Psychiatry 2013, 18(5):543-556.
37. Suzuki T., Remington G., Mulsant B.H., Uchida H., Rajji T.K., Graff-Guerrero A., Mimura M., Mamo D.C. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012, 197(1-2):1-6.
38. Tiihonen J., Wahlbeck K., Lonnqvist J., Klaukka T., Ioannidis J.P., Volavka J., Haukka J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006, 333(7561):224.
39. Tugg L.A., Desai D., Prendergast P., Remington G., Reed K., Zipursky R.B. Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects. Schizophr. Res. 1997, 25(1):71-78.
40. Yoshihashi H., Maeyama K., Kosaki R., Ogata T., Tsukahara M., Goto Y., Hata J., Matsuo N., Smith R.J., Kosaki K. Imprinting of human GRB10 and its mutations in two patients with Russell-Silver syndrome. Am. J. Hum. Genet. 2000, 67(2):476-482.